<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01458730</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT No 2006-004772-12</org_study_id>
    <nct_id>NCT01458730</nct_id>
  </id_info>
  <brief_title>Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma</brief_title>
  <official_title>Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomide.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Cancer Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mundipharma Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the efficacy and tolerability of a multiagent&#xD;
      chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma&#xD;
      in the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is&#xD;
&#xD;
        1. To investigate the efficacy and safety of a high-dose methotrexate-based induction&#xD;
           polychemotherapy regimen combined with Rituximab and intraspinal DepoCyte followed by&#xD;
           temozolomide maintenance treatment in newly diagnosed primary central nervous system&#xD;
           lymphoma&#xD;
&#xD;
        2. To assess the long term outcome concerning neurotoxicity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>at completion of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurotoxicity</measure>
    <time_frame>1-10 years after completion of therapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">66</enrollment>
  <condition>Central Nervous System Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy</intervention_name>
    <description>Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically verified primary central nervous system lymphoma No prior PCNSL&#xD;
             treatment.&#xD;
&#xD;
          -  Patients treated with steroids alone are eligible&#xD;
&#xD;
          -  No signs of lymphoma outside the CNS&#xD;
&#xD;
          -  ECOG performance status 0-4&#xD;
&#xD;
          -  Age &gt; 17 and &lt; 76 years&#xD;
&#xD;
          -  Written informed consent from the patient or guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac failure &gt; 3&#xD;
&#xD;
          -  Pregnancy or lactation. Women of childbearing potential are requested to use an&#xD;
             effective method of contraception to avoid pregnancy for a period from entry to the&#xD;
             study and at least 3 months after the last study medication&#xD;
&#xD;
          -  Previous malignancy unless disease free for at least five years&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  Regarding tuberculosis, patients at risk should be tested for latent TB according&#xD;
             local practice at each treating centre.&#xD;
&#xD;
          -  Positive HIV status&#xD;
&#xD;
          -  Organ transplantation&#xD;
&#xD;
          -  Serious psychiatric illness&#xD;
&#xD;
          -  Prior radiotherapy to the brain&#xD;
&#xD;
          -  Concomitant anti-inflammatory medication that cannot be discontinued&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 ml/minute calculated by Cockcroft and Gault formula&#xD;
&#xD;
          -  Peripheral blood count with granulocytes &lt;1.5 x 109L or platelets &lt; 100 x 109L&#xD;
&#xD;
          -  Serum bilirubin &gt;1.5 times or ASAT and alkaline phosphatase &gt;2 times upper limits of&#xD;
             normal.&#xD;
&#xD;
          -  Known anaphylaxis or IgE-mediated hypersensitivity to murine protein or any component&#xD;
             of Rituximab excludes patients from Rituximab treatment, but not from the remaining&#xD;
             part of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Elisa Jacobsen Pulczynski</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>November 15, 2012</last_update_submitted>
  <last_update_submitted_qc>November 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCNSL</keyword>
  <keyword>Immunochemotherapy</keyword>
  <keyword>Intraspinal Depocyt</keyword>
  <keyword>Maintenance temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

